Adverum Biotechnologies IncNASDAQ:ADVM
- LAST PRICE7.1800
- TODAY'S CHANGE (%)0.2900 (4.2090%)
- Bid / Lots7.0100/ 1
- Ask / Lots8.2000/ 3
- Open / Previous Close6.9400 / 6.8900
- Day Range
- 52 Week Range
- Volume215,151
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ADVM |
|---|---|---|
| 09:32 ET | 729 | 6.94 |
| 09:34 ET | 300 | 6.89 |
| 09:36 ET | 200 | 6.97 |
| 09:38 ET | 1100 | 7.06 |
| 09:39 ET | 100 | 7.035 |
| 09:41 ET | 1184 | 7.06 |
| 09:43 ET | 1100 | 7.015 |
| 09:45 ET | 11792 | 7.04 |
| 09:50 ET | 200 | 7.06 |
| 09:52 ET | 200 | 7.07 |
| 09:54 ET | 734 | 7.07 |
| 09:56 ET | 1490 | 7.15 |
| 09:59 ET | 200 | 7.14 |
| 10:03 ET | 300 | 7.1256 |
| 10:06 ET | 1397 | 7.17 |
| 10:08 ET | 1222 | 7.14 |
| 10:10 ET | 412 | 7.145 |
| 10:12 ET | 100 | 7.17 |
| 10:14 ET | 200 | 7.18 |
| 10:15 ET | 300 | 7.18 |
| 10:17 ET | 100 | 7.16 |
| 10:19 ET | 1571 | 7.1 |
| 10:21 ET | 576 | 7.14 |
| 10:24 ET | 200 | 7.16 |
| 10:26 ET | 3003 | 7.22 |
| 10:28 ET | 804 | 7.18 |
| 10:30 ET | 100 | 7.19 |
| 10:32 ET | 400 | 7.16 |
| 10:35 ET | 100 | 7.12 |
| 10:37 ET | 500 | 7.135 |
| 10:39 ET | 100 | 7.135 |
| 10:42 ET | 300 | 7.135 |
| 10:44 ET | 1713 | 7.22 |
| 10:48 ET | 848 | 7.2 |
| 10:50 ET | 1827 | 7.23 |
| 10:51 ET | 300 | 7.23 |
| 10:53 ET | 1188 | 7.26 |
| 10:55 ET | 200 | 7.23 |
| 10:57 ET | 700 | 7.24 |
| 11:00 ET | 807 | 7.21 |
| 11:04 ET | 200 | 7.24 |
| 11:06 ET | 400 | 7.21 |
| 11:08 ET | 515 | 7.175 |
| 11:09 ET | 300 | 7.1899 |
| 11:11 ET | 600 | 7.13 |
| 11:13 ET | 317 | 7.15 |
| 11:15 ET | 700 | 7.05 |
| 11:22 ET | 200 | 7.085 |
| 11:26 ET | 100 | 7.05 |
| 11:27 ET | 1067 | 7.03 |
| 11:33 ET | 200 | 7.06 |
| 11:38 ET | 655 | 7 |
| 11:44 ET | 100 | 7.04 |
| 11:45 ET | 200 | 7.01 |
| 11:47 ET | 100 | 7.01 |
| 11:49 ET | 100 | 7.04 |
| 11:54 ET | 2371 | 6.99 |
| 11:56 ET | 4026 | 7.04 |
| 11:58 ET | 1841 | 7.01 |
| 12:03 ET | 413 | 7 |
| 12:05 ET | 300 | 6.99 |
| 12:07 ET | 729 | 6.975 |
| 12:09 ET | 400 | 6.96 |
| 12:12 ET | 600 | 6.95 |
| 12:14 ET | 2000 | 7.01 |
| 12:18 ET | 300 | 7.04 |
| 12:20 ET | 100 | 7.04 |
| 12:21 ET | 905 | 7.03 |
| 12:25 ET | 413 | 7.07 |
| 12:27 ET | 100 | 7.07 |
| 12:30 ET | 100 | 7.07 |
| 12:32 ET | 100 | 7.07 |
| 12:34 ET | 300 | 7.07 |
| 12:36 ET | 200 | 7.045 |
| 12:38 ET | 1481 | 7.08 |
| 12:39 ET | 5000 | 7.057 |
| 12:41 ET | 1622 | 7.08 |
| 12:45 ET | 8581 | 7.05 |
| 12:48 ET | 325 | 7.13 |
| 12:52 ET | 500 | 7.14 |
| 12:54 ET | 300 | 7.17 |
| 12:56 ET | 1557 | 7.15 |
| 12:57 ET | 100 | 7.1999 |
| 01:01 ET | 100 | 7.17 |
| 01:03 ET | 1268 | 7.17 |
| 01:06 ET | 300 | 7.15 |
| 01:12 ET | 278 | 7.1763 |
| 01:14 ET | 200 | 7.11 |
| 01:15 ET | 200 | 7.15 |
| 01:17 ET | 100 | 7.19 |
| 01:19 ET | 400 | 7.11 |
| 01:21 ET | 300 | 7.17 |
| 01:24 ET | 400 | 7.145 |
| 01:26 ET | 200 | 7.11 |
| 01:28 ET | 300 | 7.145 |
| 01:30 ET | 300 | 7.145 |
| 01:32 ET | 200 | 7.11 |
| 01:33 ET | 400 | 7.11 |
| 01:37 ET | 400 | 7.11 |
| 01:39 ET | 500 | 7.11 |
| 01:42 ET | 300 | 7.11 |
| 01:44 ET | 400 | 7.12 |
| 01:46 ET | 300 | 7.12 |
| 01:48 ET | 400 | 7.18 |
| 01:50 ET | 300 | 7.15 |
| 01:51 ET | 400 | 7.12 |
| 01:53 ET | 2286 | 7.21 |
| 01:55 ET | 1363 | 7.18 |
| 01:57 ET | 700 | 7.22 |
| 02:00 ET | 4401 | 7.21 |
| 02:02 ET | 905 | 7.225 |
| 02:04 ET | 4140 | 7.28 |
| 02:06 ET | 175 | 7.3 |
| 02:08 ET | 967 | 7.28 |
| 02:11 ET | 3298 | 7.25 |
| 02:13 ET | 500 | 7.22 |
| 02:18 ET | 300 | 7.26 |
| 02:22 ET | 100 | 7.27 |
| 02:24 ET | 100 | 7.27 |
| 02:26 ET | 1121 | 7.23 |
| 02:27 ET | 100 | 7.22 |
| 02:29 ET | 717 | 7.24 |
| 02:31 ET | 514 | 7.21 |
| 02:40 ET | 100 | 7.21 |
| 02:42 ET | 100 | 7.25 |
| 02:44 ET | 1000 | 7.195 |
| 02:45 ET | 300 | 7.18 |
| 02:47 ET | 100 | 7.18 |
| 02:49 ET | 200 | 7.18 |
| 02:51 ET | 978 | 7.21 |
| 02:54 ET | 1816 | 7.19 |
| 02:56 ET | 200 | 7.16 |
| 02:58 ET | 300 | 7.17 |
| 03:00 ET | 400 | 7.15 |
| 03:03 ET | 800 | 7.16 |
| 03:05 ET | 300 | 7.16 |
| 03:07 ET | 649 | 7.16 |
| 03:09 ET | 300 | 7.14 |
| 03:12 ET | 1432 | 7.145 |
| 03:14 ET | 700 | 7.17 |
| 03:16 ET | 100 | 7.165 |
| 03:20 ET | 100 | 7.165 |
| 03:21 ET | 200 | 7.165 |
| 03:23 ET | 2736 | 7.19 |
| 03:25 ET | 1206 | 7.175 |
| 03:27 ET | 100 | 7.185 |
| 03:30 ET | 530 | 7.17 |
| 03:32 ET | 100 | 7.17 |
| 03:34 ET | 372 | 7.17 |
| 03:36 ET | 300 | 7.17 |
| 03:38 ET | 835 | 7.16 |
| 03:41 ET | 100 | 7.16 |
| 03:43 ET | 300 | 7.15 |
| 03:45 ET | 1102 | 7.14 |
| 03:48 ET | 453 | 7.14 |
| 03:50 ET | 1504 | 7.17 |
| 03:52 ET | 1017 | 7.18 |
| 03:54 ET | 1852 | 7.19 |
| 03:56 ET | 6326 | 7.18 |
| 03:57 ET | 3475 | 7.18 |
| 03:59 ET | 2443 | 7.18 |
Jun 25, 2024
DJ Adverum Biotechnologies Initiated at Outperform by Oppenheimer, from 8:41AM ET on Tuesday Jun 25, 2024 by Dow Jones
8:41AM ET on Tuesday Jun 25, 2024 by Dow Jones
Jun 18, 2024
Adverum Biotechnologies to Participate in TD Cowen's Genetic Medicines & RNA Summit, from 8:00AM ET on Tuesday Jun 18, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 18, 2024 by Dow Jones
Jun 11, 2024
Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szil rd Kiss as a Member of the Board of Directors, from 8:00AM ET on Tuesday Jun 11, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 11, 2024 by Dow JonesPress Release: Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szil rd Kiss as a Member of the Board of Directors, from 8:00AM ET on Tuesday Jun 11, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Adverum Biotechnologies Inc | 143.0M | -0.7x | --- |
Generation Bio Co | 143.7M | -0.9x | --- |
Quantum-Si Inc | 131.8M | -1.5x | --- |
Acumen Pharmaceuticals Inc | 138.8M | -2.2x | --- |
Invivyd Inc | 137.2M | -0.6x | --- |
Atossa Therapeutics Inc | 137.1M | -4.9x | --- |
Company Information
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
Contact Information
- Headquarters
- 100 Cardinal WayREDWOOD CITY, CA, United States 94063
- Phone
- 650-649-1004
- Fax
- 650-329-8151
Executives
- Independent Chairman of the Board
- Patrick Machado
- President, Chief Executive Officer, Director
- Laurent Fischer
- Chief Financial Officer
- Linda Rubinstein
- Chief Operating Officer
- Kishor Soparkar
- Chief Medical Officer
- Rabia Ozden
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $143.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 20.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.06 |
EPS | $-10.23 |
Book Value | $8.23 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
